Edwards Lifesciences announced the company’s EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter treatment of eligible patients with tricuspid regurgitation. The EVOQUE system is the world’s first transcatheter valve replacement therapy to receive regulatory approval to treat TR.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences price target lowered to $90 from $102 at Mizuho
- Edwards Lifesciences initiated with a Market Perform at Leerink
- Edwards Lifesciences price target lowered to $83 from $105 at Truist
- Edwards Lifesciences put volume heavy and directionally bearish
- Citi cuts Edwards Lifesciences target, opens ‘negative catalyst watch’
